Related Experiment Video
Updated: Aug 18, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer
Abstract:
Indications for checkpoint inhibitors (CPIs) are growing rapidly within the field of oncology; however, they continue to have heterogeneous outcomes in different cancers. Other than mismatch repair deficiency, there are no consistent tests to determine a tumor's susceptibility. By exploring factors beyond the cancer cell, researchers have learned that the efficacy of CPIs may be governed by a myriad of variable host factors, including the tumor microenvironment (TME) and gut microbiome (GMB). The GMB serves as one of the primary organs of immune defense and has well-established local and systemic effects on the host immune system. Recent investigations suggest that the GMB also affects the TME. This review article discusses the concepts of a TME and a GMB and their effects on responses to CPIs. It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer. By highlighting this important pathophysiologic process, we hope to provide insight into a possible explanation for differences in interindividual response to CPIs, discuss a potential method for transferring treatment efficacy between patients, and propose a method for expanding the use of CPIs to prostate cancer.
Insights
Checkpoint inhibitors (CPIs) show varied effectiveness across cancers. Host factors like the tumor microenvironment (TME) and gut microbiome (GMB) significantly influence CPI response, offering new therapeutic avenues.
Area of Science:
- Oncology
- Immunology
- Microbiome Research
Background:
- Checkpoint inhibitors (CPIs) are increasingly used in oncology but have inconsistent patient outcomes.
- Tumor susceptibility to CPIs is not reliably predicted, except for mismatch repair deficiency.
- Host factors, including the tumor microenvironment (TME) and gut microbiome (GMB), are emerging as critical determinants of CPI efficacy.
Purpose of the Study:
- To review the roles of the TME and GMB in modulating CPI responses.
- To explore the interplay between the GMB, TME, and CPI efficacy.
- To discuss the application of these concepts to improving CPI use in prostate cancer.
Main Methods:
- Literature review of existing research on CPIs, TME, and GMB.
- Analysis of studies investigating the influence of GMB on TME and systemic immunity.
- Synthesis of findings to propose new strategies for CPI therapy.
Main Results:
- The GMB influences the TME, impacting local and systemic immune responses.
- Host factors significantly contribute to the heterogeneity of CPI treatment outcomes.
- Understanding the GMB-TME axis may explain inter-individual variations in CPI effectiveness.
Conclusions:
- The GMB and TME are crucial, yet often overlooked, factors in CPI therapy.
- Modulating the GMB and TME could enhance CPI efficacy and broaden their application.
- Further research into these host factors may lead to personalized CPI strategies and improved treatment for prostate cancer.
More Related Videos
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
06:07Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
Related Concept Videos
01:18Dysbiosis of the Gut Microbiota
01:21Microbiota Modulation by Antibiotics